These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20417865)

  • 1. Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer.
    Silva Soares EW; de Lima Santos SC; Bueno AG; Cavalli IJ; Cavalli LR; Fouto Matias JE; de Souza Fonseca Ribeiro EM
    Cancer Genet Cytogenet; 2010 May; 199(1):24-30. PubMed ID: 20417865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
    Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
    Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
    Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
    Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
    Utada Y; Haga S; Kajiwara T; Kasumi F; Sakamoto G; Nakamura Y; Emi M
    Cancer; 2000 Mar; 88(6):1410-6. PubMed ID: 10717624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
    Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
    Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
    Isaacs C; Cavalli LR; Cohen Y; Pennanen M; Shankar LK; Freedman M; Singh B; Liu M; Gallagher A; Rone JD; Dickson RB; Sidransky D; Haddad BR
    Breast Cancer Res Treat; 2004 Mar; 84(2):99-105. PubMed ID: 14999140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
    Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
    Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
    Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FHIT gene in gastric cancer: association with tumour progression and prognosis.
    Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
    J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
    Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
    Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.
    Santos SC; Cavalli LR; Cavalli IJ; Lima RS; Haddad BR; Ribeiro EM
    J Clin Pathol; 2004 Apr; 57(4):374-7. PubMed ID: 15047740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
    Ismail HM; Medhat AM; Karim AM; Zakhary NI
    Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
    Charef-Hamza S; Trimeche M; Ziadi S; Amara K; Gaddas N; Mokni M; Sriha B; Yacoubi T; Korbi S
    Cancer Lett; 2005 Jun; 224(2):185-91. PubMed ID: 15914269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
    Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
    Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
    Becker K; Goldberg M; Helmbold P; Holbach LM; Loeffler KU; Ballhausen WG
    Br J Dermatol; 2008 Dec; 159(6):1282-9. PubMed ID: 18717684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.
    Hampl JA; Hampl M; Reiss G; Koch R; Saeger HD; Schackert HK
    Anticancer Res; 2004; 24(1):281-90. PubMed ID: 15015609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
    Cavalli LR; Singh B; Isaacs C; Dickson RB; Haddad BR
    Cancer Genet Cytogenet; 2004 Feb; 149(1):38-43. PubMed ID: 15104281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.